Results 171 to 180 of about 38,272 (314)

SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF ‐2α signaling pathway in arrhythmogenic cardiomyopathy [PDF]

, 2022
Zhe Yang, Tengling Li, Jianzhong Xian, Jia Chen, Yin Huang, Qin Zhang, Xiufang Lin, Hongyun Lu, Yubi Lin   +8 more
openalex   +1 more source

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.

The Lancet Diabetes and Endocrinology, 2021
David C. Wheeler, David C. Wheeler, B. Stefánsson, N. Jongs, G. Chertow, T. Greene, F. Hou, J. McMurray, R. Correa-Rotter, P. Rossing, P. Rossing, R. Toto, C. Sjöström, A. Langkilde, H. Heerspink, H. Heerspink   +15 more
semanticscholar   +1 more source

Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis

Journal of Bioenergetics and Biomembranes
Septic cardiomyopathy is a severe cardiovascular disease with a poor prognosis. Previous studies have reported the involvement of ferroptosis in the pathogenesis of septic cardiomyopathy.
Ke Hu, Pin Jiang, Jiaxing Hu, Bing Song, Ya Hou, Jinxuan Zhao, Haiting Chen, Jun Xie   +7 more
semanticscholar   +1 more source

Ethnic differences in the comparative effectiveness of second‐line type 2 diabetes medications in preventing cardiovascular disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1013-1023, February 2026.
Abstract Aim To investigate ethnic differences in the comparative effectiveness of sulfonylureas (SU), dipeptidyl peptidase‐4 inhibitors (DPP4i) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) on cardiovascular outcomes. Materials and Methods We identified adults with type 2 diabetes in UK electronic health records initiating SU, DPP4i or SGLT2i
Mia Harley, Christopher T. Rentsch, Elizabeth Williamson, Anoop S. V. Shah, Patrick Bidulka, Charlotte Warren‐Gash, Marleen Bokern, Rohini Mathur   +7 more
wiley   +1 more source

Dapagliflozin as an autophagic enhancer via LKB1/AMPK/SIRT1 pathway in ovariectomized/d-galactose Alzheimer’s rat model [PDF]

, 2022
Weam W. Ibrahim, Ahmed S. Kamel, Ahmed Wahid, Noha F. Abdelkader   +3 more
openalex   +1 more source

SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register‐based randomised trial on prevention of diabetic complications

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1327-1338, February 2026.
Abstract Aims Metformin has hitherto not been proven superior to other type 2 diabetes (T2D) medications for the prevention of organ complications. The aim of this study is to report baseline data and blinded interim analyses in the register‐based randomised clinical trial (RRCT) SMARTEST, which compares metformin and the SGLT2 inhibitor dapagliflozin ...
Jan W. Eriksson, Giovanni Fanni, Martin H. Lundqvist, Stefan Jansson, Karin Rådholm, Sheyda Sofizadeh, Vagia Patsoukaki, Albert Nilsson, Daniel Lindholm, Olov Rolandsson, Anna Norhammar, Elisabet Granstam, Björn Eliasson, Louise Bennet, Johan Sundström   +14 more
wiley   +1 more source

Author response for "Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes"

, 2019
Amalia Gastaldelli, Enrico Repetto, Cristian Guja, Elise Hardy, Jenny Han, Serge Jabbour, Ele Ferrannini   +6 more
openalex   +1 more source

Review for "Effects of 6weeks treatment with dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: a randomized placebo-controlled exploratory study"

, 2020

openalex   +1 more source

Effects of dapagliflozin on type 2 diabetes and other metabolic disorders: Results from a prospective, observational DIATOM study

, 2023
Aneeket T Marwah, Tiven R Marwah, Khushali P. Parikh, Supriya Malhotra   +3 more
openalex   +1 more source

Heart matters: How glucose‐ and lipid‐modulating drugs remodel epicardial adipose tissue accumulation, inflammatory patterns and browning

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 878-894, February 2026.
Abstract Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot located between the myocardium and the visceral pericardium, exerting direct paracrine and vasocrine effects on the heart and coronary vessels. Under physiological conditions, EAT supports myocardial energy metabolism and thermoregulation through fatty acid supply and
Elisabeth Heuboeck, Charnkamal Singh Bhogal, Markus Mandl   +2 more
wiley   +1 more source